Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases.

Gate Bioscience

Jordi Mata-Fink

Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. Humans produce over 4,000 distinct extracellular proteins, more than 1,000 of which can drive disease when they act improperly, misfold, or are made at the wrong time, in the wrong place, or at incorrect levels. By eliminating these disease-causing proteins, we aim to eliminate diseases for patients. Molecular Gates act by a completely new therapeutic mechanism. All extracellular proteins pass through single channel in the cell as they are secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the harmful protein is degraded by the cell instead of being secreted. Our mission to create Molecular Gate medicines is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at www.gatebio.com.

Bioinformatics Organizations

Software Companies

Andreessen Horowitz

Versant Ventures

Arch Venture Partners

Venture capital investment arm of Alphabet Inc.

Brisbane

City in San Mateo County, California, United States

United States of America

Country primarily located in North America

California

San Mateo County

South San Francisco

Custom Computer Programming Services

Computer Systems Design and Related Services

Professional, Scientific, and Technical Services

Software Publishers

Publishing Industries

Information

Publishing Industries (except Internet)

Computer Programming Services

Computer Programming, Data Processing, And Other Computer Related

Business Services

Prepackaged Software

Google Hosted Libraries

Google Font API

core-js

webflow

jQuery

vimeo

Gate Bioscience Reviews